Table 2.
Adverse effects of the Xraphconn® treatment, grades of adverse effects, day of first appearance, and respective symptomatic treatment. 1 Heinz body formation: mild (5–9.9% of red blood cells), moderate (10–25% of red blood cells), severe (>25% of red blood cells); 2 lymphocytosis: mild (4–7.9 × 109/L), moderate (8–15 × 109/L), severe (>15 × 109/L) 3 was already present on day 0: lymphocytosis: 5/14 cats; eosinophilia: 1/11 4 eosinophilia: mild (0.6–1.9 × 109/L), moderate (2–10 × 109/L), severe (>10 × 109/L); 5 increased liver enzymes: increased alanine aminotransferase (ALT) activity: mild (ALT < 200 IU/L), moderate (ALT 200–350 IU/L), severe (ALT >350 IU/L); increased alkaline phosphatase (AP): mild (AP < 200 IU/L), moderate (AP 200–350 IU/L), severe (AP > 350 IU/L).
| Adverse Effect | Number of Cats | Grade | Median Day of First Appearance (Range) | Symptomatic Treatment | |
|---|---|---|---|---|---|
| Heinz body formation 1 | 1/18 | moderate | 83 | S-adenosyl-methionine | |
| 14/18 3 | 4/14 | mild | 4.5 (2–83) | no | |
| Lymphocytosis 2 | 6/14 | moderate | 1 (0–28) | no | |
| 4/14 | severe | 1 (0–2) | no | ||
| Eosinophilia 4 | 11/18 3 | 11/11 | mild | 14 (0–28) | no |
| increased liver enzyme activity 5 | 8/11 | mild | 28 (2–83) | no | |
| 11/18 | 1/11 | moderate | 4 | no | |
| 2/11 | severe | 4 | silymarin |